MyRisk TestSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular ...

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes.

Radboudumc is the first hospital in the world to use a new genetic test on a large scale in clinical practice. This test ...

Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.

Charlotte Chilton says Conor Maynard's negative paternity tests could be explained by a rare genetic condition - so how ...

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...

Get key insights from Myriad Genetics’ Q3 2025 earnings call, growth strategies, financial outlook, and new product launches.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...